A cancer diagnosis does not end at treatment. For most people it opens a long, quiet chapter of surveillance - MRI scans at set intervals, for years, sometimes for life. The scans matter. The intervals matter. And nobody sits you down to explain how any of it actually works, why your first year of follow-up looks nothing like your fifth, or what the words "stable disease" and "no new lesions" really mean when you read them on your report.
This piece is written for patients living inside that chapter. It is about surveillance MRI in the UK in 2026 - the protocols, the schedules, the thresholds that trigger action, and the things a good MRI service should give you at every follow-up visit.
The one-line answer
Surveillance MRI is a planned series of scans, at intervals set by your cancer team, whose only job is to catch recurrence or progression early enough to change what happens next. It is not a general health check. Every image is compared to every image before it, and the report reads change - not a snapshot.
Why surveillance MRI exists
The blunt reason is that recurrence is often silent. Many cancers return quietly, without symptoms, in the months and years after the primary treatment is finished. By the time a person notices, the disease has usually moved from something small and local to something larger and harder to treat. Surveillance imaging exists to close that gap.
There are three distinct clinical reasons your oncologist keeps you on a scan schedule. First, early detection of recurrence - finding a new lesion when it is one centimetre and treatable, not when it is symptomatic. Second, disease modification - some cancers, particularly slow-growing prostate, low-grade glioma and certain sarcomas, live on active surveillance, where the scan is the decision-making tool for when to intervene at all. Third, changing treatment before symptoms return - a rising area of change on MRI often triggers a switch of systemic therapy weeks or months before the patient would have felt anything, and those weeks can matter.
The unglamorous truth is that most surveillance scans are normal. That is the point. You are buying certainty, cheaply, at the price of an hour on a scanner every few months.
Common cancer surveillance MRI protocols
Every cancer has its own surveillance rhythm, and it is worth knowing yours in some detail. A few of the most common in UK practice:
| Cancer | Typical MRI protocol | Baseline schedule |
|---|---|---|
| High-risk breast (BRCA, dense breast, prior DCIS) | Annual bilateral breast MRI with contrast, paired with mammography | Annual, indefinite |
| Prostate on active surveillance | mpMRI (T2, DWI, dynamic contrast) | 12 months, then 36 months, then triggered by PSA |
| Post-glioma brain | Contrast-enhanced brain MRI with perfusion | 3-monthly year 1, 6-monthly years 2 to 5, annual after |
| Hepatocellular carcinoma (post-resection or post-ablation) | Multiphase liver MRI with gadoxetate | 3-monthly year 1, 6-monthly thereafter |
| Soft-tissue sarcoma | Local-site MRI with contrast, plus chest CT | 3 to 6-monthly years 1 to 3, then annual |
| Rectal cancer post-treatment | Pelvic MRI with DWI | 6-monthly years 1 to 2, then annual |
These are typical UK practice patterns, not personal advice. Your own schedule is set by your oncologist and multi-disciplinary team on the basis of tumour biology, treatment received and personal risk factors.
What a "stable" report actually means
Radiologists reporting oncology follow-up almost always use a formal scoring system called RECIST 1.1, and understanding it removes most of the anxiety around the wording of your report.
RECIST measures the longest diameter of up to five "target lesions" - the pieces of disease chosen at baseline as representative. Every subsequent scan re-measures those same lesions, and the numbers are added up.
- Complete response: all target lesions gone.
- Partial response: the sum has decreased by 30 per cent or more.
- Stable disease: neither of the above, and no new lesion. This is the report most surveillance patients receive.
- Progressive disease: a 20 per cent increase in the sum of measurements, or any new lesion of significance.
A "stable" report is genuinely good news. It does not mean the disease is cured, and it does not mean it will always be stable, but on this particular scan, at this particular interval, the pattern is holding. That is what surveillance is designed to confirm.